On Air Now

Upcoming Shows

Program Schedule »

Tune in to Listen

1440 AM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
60° Feels Like: 60°
Wind: ESE 5 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Partly Cloudy 60°

Tomorrow

Thunderstorms 74°

Fri Night

Heavy Thunderstorms 64°

Alerts

  • 0 Severe Weather Alerts
  • 0 Cancellations

Bayer's Nexavar gets priority review as thyroid cancer drug

A plant belonging to Germany's largest drugmaker Bayer is seen in Leverkusen January 30, 2013. REUTERS/Ina Fassbender
A plant belonging to Germany's largest drugmaker Bayer is seen in Leverkusen January 30, 2013. REUTERS/Ina Fassbender

FRANKFURT (Reuters) - Bayer's cancer drug Nexavar was given priority review status by U.S. healthcare regulators for the oral drug's use against a difficult-to-treat type of thyroid cancer, the company said on Tuesday.

The U.S. Food and Drug Administration aims to complete the priority review within six months, rather than the standard review of about 10 months, Bayer said.

Bayer and development partner Onyx Pharmaceuticals are seeking a wider use for Nexavar to include treatment of patients with thyroid cancer that returned despite previous surgery and treatment with radioactive iodine, a group with a particularly poor prospect of survival.

Nexavar is already approved to treat liver as well as kidney cancer and it is also being tested on breast cancer patients.

(Reporting by Ludwig Burger)

Comments